Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that its first‑in‑class oral inhibitor Iptacopan (Fabhalta) has received additional approval from the China National Medical Products Administration (NMPA) for the treatment of IgA nephropathy (IgAN).
Contents
What is Iptacopan?
- Target – Selectively inhibits complement factor B, a key driver of the alternative complement pathway.
- Current Indications –
- Paroxysmal nocturnal hemoglobinuria (PNH) – Approved April 2024; expanded May 2025 to all adult PNH patients, including those previously treated with complement inhibitors.
- C3 glomerulopathy (C3G) – Approved April 2025; reduces proteinuria in adult patients.
- New Indication – IgA nephropathy (IgAN) – First oral complement‑inhibitor therapy approved for this common glomerular disease.
Clinical Evidence Supporting the IgAN Approval
| Parameter | Iptacopan | Placebo | % Reduction |
|---|---|---|---|
| Morning urine protein‑to‑creatinine ratio (UPCR) at 2 weeks | Rapid decline | No change | – (rapid efficacy) |
| Proteinuria at 9 months | 38.3% ↓ | 0% ↓ | 38.3 % |
| Safety/Tolerability | Mild adverse events; no serious safety signals | – | – |
The pivotal Phase 3 study demonstrated a 38.3 % reduction in proteinuria after 9 months, with a favorable safety profile and rapid onset of action—key factors that enabled the NMPA’s approval.
Broader Development Pipeline
Novartis is advancing Iptacopan across a spectrum of complement‑mediated disorders, including:
- Atypical hemolytic uremic syndrome (aHUS)
- Immune‑complex membranoproliferative glomerulonephritis (IC‑MPGN)
- Lupus nephritis (LN)
This portfolio underscores Novartis’s commitment to transforming complement‑driven diseases worldwide.
Market Implications
- First Oral Therapy – Iptacopan’s oral route offers a convenient alternative to injectable complement inhibitors, potentially improving patient adherence.
- China’s Growing Biopharma Market – The IgAN approval positions Novartis to capture a large patient pool in China, where IgAN prevalence is rising.
- Competitive Edge – By expanding into multiple renal indications, Novartis strengthens its foothold against other complement‑targeted agents.
Next Steps
- Launch in China – Commercial rollout slated for Q4 2025.
- Real‑World Evidence – Post‑marketing studies to confirm long‑term efficacy and safety.
- Global Expansion – Leverage China data to support regulatory submissions in the EU and US for IgAN and other renal indications.-Fineline Info & Tech
